A Case of Hidradenitis Suppurativa Responsive to Testosterone Replacement Therapy

This case study describes a 36-year-old female with Hidradenitis Suppurativa (HS) who experienced significant improvement after starting testosterone replacement therapy for gender transition. Despite previous treatments with antibiotics and biologics like adalimumab and tildrakizumab, her condition persisted. However, after receiving intramuscular testosterone, her groin lesions resolved completely, and she remained biologic-free for 20 weeks without new lesions. The study suggests that exogenous testosterone may suppress endogenous hormone production, reducing inflammation in HS lesions. While the exact mechanism remains unclear, this case highlights the potential role of testosterone in managing HS.